Biodexa PharmaceuticalsBDRX
13F holders, Q1 2026 (March 31)7holders −1
1new positions
2sold out
$0.62avg. 13F price*
At the end of Q1 2026, 7 institutions reported holding Biodexa Pharmaceuticals PLC (BDRX) in their 13F filings, down 1 from Q4 2025. 1 opened new positions and 2 sold out. The largest holders were Sabby Management, LLC ($159K), Armistice Capital, LLC ($60K) and GAMMA Investing LLC ($9K).
- Company
- Biodexa Pharmaceuticals PLC
- CUSIP
- 59564R880
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1 |
| Exits | 2 | $24K |
All 13F filers, Q4 2025 → Q1 2026: 78,818 shares bought and 15,141 shares sold, net +63,677 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Sabby Management, LLC | 3.01% | Add +35.0% | 257,472 | $159K |
| Armistice Capital, LLC | 0.00% | Reduce -2.5% | 97,521 | $60K |
| GAMMA Investing LLC | 0.00% | Add +675.5% | 13,780 | $9K |
| UBS Group AG | 0.00% | Reduce -94.0% | 127 | $78 |
| Hilton Head Capital Partners, LLC | 0.00% | No change | 30 | $19 |
| Rhumbline Advisers | 0.00% | Reduce -20.8% | 19 | $11 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 1 | $1 |
"% of holder's portfolio" is BDRX's weight in each manager's 13F, not the share of Biodexa Pharmaceuticals PLC the manager owns.